MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Feb 7, 2015Clinical cancer research : an official journal of the American Association for Cancer Research

MGMT Promoter Methylation Predicts Benefit from Higher-Dose Temozolomide Retreatments in Advanced Glioblastoma

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

The trial was closed after 105 patients were enrolled, showing similar median time-to-treatment failure of 1.8 months for one regimen and 2.0 months for another.

Both treatment arms demonstrated comparable outcomes in median time-to-treatment failure and overall survival.
Median time-to-treatment failure was 3.2 months for patients with MGMT-methylated tumors compared to 1.8 months for those with unmethylated tumors.
Progression-free survival rates at 6 months were significantly higher at 39.7% for patients with MGMT promoter methylation, compared to 6.9% for those without.
Temozolomide rechallenge may be a viable option for patients with MGMT promoter-methylated recurrent glioblastoma.
Alternative treatment strategies could be needed for patients with progressive glioblastoma lacking MGMT promoter methylation.

AI simplified

PURPOSE: Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules. The DIRECTOR trial sought to show superiority of the 7/14 regimen.

EXPERIMENTAL DESIGN: Patients with glioblastoma at first progression after TMZ/RT→TMZ and at least two maintenance temozolomide cycles were randomized to Arm A [one week on (120 mg/m(2) per day)/one week off] or Arm B [3 weeks on (80 mg/m(2) per day)/one week off]. The primary endpoint was median time-to-treatment failure (TTF) defined as progression, premature temozolomide discontinuation for toxicity, or death from any cause. O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation was prospectively assessed by methylation-specific PCR.

RESULTS: Because of withdrawal of support, the trial was prematurely closed to accrual after 105 patients. There was a similar outcome in both arms for median TTF [A: 1.8 months; 95% confidence intervals (CI), 1.8-3.2 vs. B: 2.0 months; 95% CI, 1.8-3.5] and overall survival [A: 9.8 months (95% CI, 6.7-13.0) vs. B: 10.6 months (95% CI, 8.1-11.6)]. Median TTF in patients with MGMT-methylated tumors was 3.2 months (95% CI, 1.8-7.4) versus 1.8 months (95% CI, 1.8-2) in MGMT-unmethylated glioblastoma. Progression-free survival rates at 6 months (PFS-6) were 39.7% with versus 6.9% without MGMT promoter methylation.

CONCLUSIONS: Temozolomide rechallenge is a treatment option for MGMT promoter-methylated recurrent glioblastoma. Alternative strategies need to be considered for patients with progressive glioblastoma without MGMT promoter methylation.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief